The entire Marken organisation was classified as essential during the pandemic, and we are still serving as the vital link between a drug in development and the patient. risk, especially in the supply chain. We always ask, will there be more regional or local manufacturing? Will we depend on fewer vendors? How will shortages or disruptions impact our decision-making? I am an avid reader, and it’s clear that our industry is changing. Marken is agile – and we will need to continue to demonstrate flexibility – consider 3D printing, digital patient (Metaverse Avatars) – so much of what is done physically today will be accomplished virtually before going into production. Can you tell us anything about what might be in store for Marken this year? At Marken, we will continue to expand access in low-and middle-income countries (LMICs) with a focus on vaccines, such as sub-Saharan Africa. In other areas our growth is in response to a demand for clinical trials, such as Japan, China, and Korea. In these areas and across the globe, we will continue to streamline our network and optimize new technology. We have the best people and the best tools – and we will continue to deliver with excellence. How do you want the world to remember you? I would like to be remembered as someone who listened, who was open and human, and who made a difference. I would like the team I helped to build (and continue to build) to have learned from me and found those insights to be useful on their personal and professional journeys. And I would like to be remembered as someone who enjoyed a good laugh! CEO Today USA Awards 2022 - 13 - - FEATURED WINNER -
RkJQdWJsaXNoZXIy Mjk3Mzkz